



## LETTER TO THE EDITOR

## Molecular basis of ligand recognition and activation of human V2 vasopressin receptor

Cell Research (2021) 31:929–931; <https://doi.org/10.1038/s41422-021-00480-2>

Dear Editor,

Vasopressin type 2 receptor (V2R) belongs to the vasopressin (VP)/oxytocin (OT) receptor subfamily of G protein-coupled receptors (GPCRs), which comprises at least four closely related receptor subtypes: V1aR, V1bR, V2R, and OTR.<sup>1</sup> These receptors are activated by arginine vasopressin (AVP) and OT, two endogenous nine-amino acid neurohypophysial hormones, which are thought to mediate a biologically conserved role in social behavior and sexual reproduction.<sup>2</sup> V2R is mainly expressed in the renal collecting duct principal cells and mediates the antidiuretic action of AVP by accelerating water reabsorption, thereby playing a vital role in controlling water homeostasis. Moreover, numerous gain-of-function and loss-of-function mutations of V2R have been identified and are closely associated with human diseases, including nephrogenic syndrome of inappropriate diuresis (NSIAD) and X-linked congenital nephrogenic diabetes insipidus (NDI).<sup>3</sup> Thus, V2R has attracted intense interest as a drug target. However, due to a lack of structural information, how AVP recognizes and activates V2R remains elusive, which hampers the V2R-targeted drug design. Here, we determined a 2.6 Å resolution cryo-EM structure of the full-length, G<sub>s</sub>-coupled human V2R bound to AVP (Fig. 1a; Supplementary information, Table S1). The G<sub>s</sub> protein was engineered based on mini-G<sub>s</sub> that was used in the crystal structure determination of the G<sub>s</sub>-coupled adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>R) to stabilize the V2R–G<sub>s</sub> protein complex (Supplementary information, Data S1).<sup>4</sup> The final structure of the AVP–V2R–G<sub>s</sub> complex contains all residues of AVP (residues 1–9), the G<sub>α</sub>, Ras-like domain, G<sub>βγ</sub> subunits, Nb35, scFv16, and the V2R residues from T31 to L339<sup>8,57</sup> (superscripts refer to Ballesteros–Weinstein numbering<sup>5</sup>). The majority of amino acid side chains, including AVP, transmembrane domain (TMD), all flexible intracellular loops (ICLs) and extracellular loops (ECLs) except for ICL3 and G185–G188 in ECL2, were well resolved in the model, refined against the EM density map (Fig. 1a; Supplementary information, Figs. S1–S3). The complex structure can provide detailed information on the binding interface between AVP and helix bundle of the receptor, as well as the receptor–G<sub>s</sub> interface.

AVP occupies an orthosteric binding pocket in the TMD bundle composed of all TM helices and ECLs (Fig. 1b, c; Supplementary information, Table S2). The most notable conformational feature of AVP is the tocin ring formed by a disulfide bridge between the first and sixth cysteine residues, presenting a “spoon-like” conformation (Supplementary information, Fig. S4a, b). The cyclic spoon head inserts deeply into the TMD core, while the C-terminal spoon tail stretches toward the ECLs of the receptor. Cys<sup>1P</sup> of AVP and Q96<sup>2,61</sup>, K116<sup>3,29</sup>, Q119<sup>3,32</sup> of V2R form a stabilizing H-bond network, consistent with the decreased potency of the receptor mutants with these residues mutated (Fig. 1b; Supplementary information, Fig. S4c, d). The hydroxyl group of Tyr<sup>2P</sup> forms an H-bond with the main chain oxygen of L312<sup>7,40</sup>, whereas its main chain CO group forms another H-bond with Q174<sup>4,60</sup> (Fig. 1b; Supplementary information, Fig. S4c). Phe<sup>3P</sup> buries in a hydrophobic cleft constituted by M120<sup>3,33</sup>, M123<sup>3,36</sup>, Y205<sup>5,38</sup>, V206<sup>5,39</sup>, I209<sup>5,42</sup>, F287<sup>6,51</sup>, F288<sup>6,52</sup>, and Q291<sup>6,55</sup> (Fig. 1b; Supplementary information, Fig. S4c). Other

polar contacts are seen between Gln<sup>4P</sup> and R202<sup>5,35</sup>, Gln<sup>4P</sup> and the backbone and side chain oxygens of Q291<sup>6,55</sup>, as well as Asn<sup>5P</sup> and the main chain of A194<sup>ECL2</sup> (Fig. 1b, c; Supplementary information, Fig. S4c). Arg<sup>8P</sup> forms salt bridges with D33<sup>1,28</sup> and E40<sup>1,35</sup>, the latter forms an extra salt bridge with K100<sup>2,65</sup> (Fig. 1c; Supplementary information, Fig. S4c). Additionally, the C-terminal amide of AVP points to ECL1, stacking against the R104<sup>ECL1</sup> guanidinium group and H-bonding to the backbone CO group of D103<sup>ECL1</sup> (Fig. 1c; Supplementary information, Fig. S4c). These interactions between AVP and residues in V2R binding pocket were confirmed through alanine mutagenesis studies using cAMP accumulation assays (Supplementary information, Fig. S4d–g and Table S4).


This structure also provides a template to study the selectivity of AVP and OT. OT has two amino acid substitutions (Phe<sup>3P</sup> to Ile<sup>3P</sup> and Arg<sup>8P</sup> to Leu<sup>8P</sup>) (Supplementary information, Fig. S5a), and exhibits a much lower selectivity against V2R as opposed to AVP.<sup>6</sup> By docking OT into the V2R binding pocket, a weaker hydrophobic interaction network is created for Ile<sup>3P</sup> compared to its equivalent residue Phe<sup>3P</sup> in AVP (Supplementary information, Fig. S5b). Additionally, the hydrophobic leucine at position 8 no longer shows the polar interactions with the receptor as compared with Arg<sup>8P</sup> of AVP (Supplementary information, Fig. S5c). Thus, the peptide-binding pocket of V2R defines a relatively unfavorable binding environment for OT in contrast to AVP.

A “DCWA” sequence in ECL2 is highly conserved throughout VP/OT receptor subfamily but is not a feature of other class A GPCRs.<sup>7</sup> Interestingly, structural comparison of the AVP–V2R–G<sub>s</sub> complex with inactive OTR (PDB: 6TPK)<sup>8</sup> reveals a notable conformational transition of ECL2 from β-hairpin to a flexible loop (Fig. 1d). In this conserved sequence, W193<sup>ECL2</sup> and A194<sup>ECL2</sup> directly contact with AVP. Asn<sup>5P</sup> may push and stack against W193<sup>ECL2</sup> and overcome the probable steric clash between Asn<sup>5P</sup> and W188<sup>ECL2</sup> of OTR, the cognate residue of V2R, which may confer this conformational transition (Fig. 1d). Although D191<sup>ECL2</sup> and C192<sup>ECL2</sup> do not directly interact with AVP, the former forms an H-bond to the F105<sup>ECL1</sup> amide and a salt-bridge to R104<sup>ECL1</sup> and the latter forms a conserved disulfide bond with C112<sup>3,25</sup>. These interactions, in turn, stabilize ECL1 and ECL2 conformations, thereby facilitating the interactions between ECL1 and the C-terminal amide of AVP (Fig. 1e; Supplementary information, Fig. S4f, g and Table S4).

A structural comparison of the AVP–V2R–G<sub>s</sub> complex with the inactive OTR supports the contention that our structure is indeed in the active state. AVP triggers the rotameric change of “toggle switch” W284<sup>6,48</sup>, initiating the rotation and a notable outward displacement of TM6, the hallmark of GPCR activation (Fig. 1f; Supplementary information, Fig. S6a).<sup>9</sup> Intriguingly, a distortion of TM7 helix was observed between L312<sup>7,40</sup> and S315<sup>7,43</sup>. This distorted conformation appears to be stabilized by the H-bond between Tyr<sup>2P</sup> of AVP and the main chain CO group of L312<sup>7,40</sup> in the receptor, drawing TM7 toward the peptide-binding pocket core (Fig. 1g). [Phe2]AVP, a synthesized AVP analog with a substitution of Tyr by Phe that abolishes this H-bond, showed decreased agonistic activity by 28-fold,<sup>10</sup> implying that the polar

Received: 17 November 2020 Accepted: 25 January 2021

Published online: 19 March 2021



**Fig. 1 Cryo-EM structure of the AVP-V2R-G<sub>s</sub> complex.** **a** Orthogonal view of the density map (left panel) and model (right panel) for the AVP-V2R-G<sub>s</sub> complex. V2R, slate blue; AVP, green; G<sub>s</sub>, orange; Gβ, salmon; Gy, cyan; Nb35, gray; scFv16, magenta; cholesterol, yellow. **b, c** Interactions between AVP and residues in V2R-binding pocket. **d, e** A comparison of the conformational change of ECL1 and ECL2 in AVP-bound V2R structure and retosiban-bound OTR (PDB: 6TPK) inactive structure. **f** Conformational changes of TM6 and conserved W<sup>6.48</sup> and Y/F<sup>6.44</sup> of V2R compared to inactive OTR. Red arrows indicate the movement of TM6 and the side chains of W<sup>6.48</sup> and Y/F<sup>6.44</sup> in V2R relative to inactive OTR. **g** Conformational change of TM7 in AVP-V2R structure relative to inactive OTR, β<sub>2</sub>AR-G<sub>s</sub>, and A<sub>2A</sub>R-G<sub>s</sub> structures. Red arrow indicates the movement of TM7 in V2R. **h** Sequence comparison of conserved P<sup>5.50</sup>-I<sup>3.40</sup>-F<sup>6.44</sup> motif among V2R, V1aR, V1bR, OTR, A<sub>2A</sub>R, and β<sub>2</sub>AR. Polar residues are colored in red and nonpolar residues in green. **i, j** Conformational changes of AVP-bound V2R structure resulted from substitutions in the conserved P<sup>5.50</sup>-I<sup>3.40</sup>-F<sup>6.44</sup> motif relative to inactive OTR (**i**) and active β<sub>2</sub>AR (**j**) structures, respectively. **k, l** A conformational comparison of receptor helical bundle and Gα<sub>s</sub> α5 helix among AVP-V2R-G<sub>s</sub>, β<sub>2</sub>AR-G<sub>s</sub>, and A<sub>2A</sub>R-G<sub>s</sub> complexes. Red arrows indicate the movements of intracellular tips of TM5, 6, and α5 helix of Gα<sub>s</sub> from V2R-G<sub>s</sub> relative to other complexes. Black arrows label the cytoplasmic ends of TM5 in these structures. H-bonds and salt bridges are depicted as red and green dashed lines, respectively. The disulfide bonds are shown as yellow sticks. The structural alignment is based on receptors.

interaction between Tyr<sup>2P</sup> and the receptor is critical to AVP-induced V2R activation. Specifically, F<sup>6.44</sup> and I<sup>3.40</sup>, residues in the conserved “P-I-F” motif in class A GPCRs, are substituted by polar residues Y280<sup>6.44</sup> and S127<sup>3.40</sup> in V2R, respectively (Fig. 1h). AVP binding triggers the rotation of Y280<sup>6.44</sup> relative to the inactive OTR (Fig. 1i), subsequently forming a featured H-bond network between Y280<sup>6.44</sup>/S127<sup>3.40</sup> and the backbone CO group of V213<sup>5.46</sup> in contrast to active β<sub>2</sub>AR (PDB: 3SN6),<sup>11</sup> which probably stabilizes the active conformation of the receptor (Fig. 1j). The disease-associated mutations S127<sup>3.40</sup>F and Y280<sup>6.44</sup>C in V2R deactivate the receptor,<sup>12,13</sup> while the replacement of F284<sup>6.44</sup> in OTR by the V2R-equivalent tyrosine converts AVP from a partial to a full agonist,<sup>14</sup> supporting the hypothesis that these unconventional “P-I-F” residues play critical roles in V2R activation. Furthermore, the cytoplasmic end of TM4 is one helical turn shorter than that of the inactive OTR,<sup>8</sup> G<sub>s</sub>-coupled β<sub>2</sub>AR<sup>11</sup> and A<sub>2A</sub>R<sup>4</sup> (PDB: 5G53), thereby releasing a longer ICL2. The ICL2 protrudes towards TM1 and adopts a C-shaped conformation (Supplementary information,

Fig. S6b). This C-shaped loop is stabilized by H-bonds formed between H80<sup>2.45</sup> and the backbone CO group of H155<sup>ICL2</sup>, as well as W71<sup>ICL1</sup> and backbone CO group of A154<sup>ICL2</sup>, and further by an intra-loop polar interaction network (Supplementary information, Fig. S6c–e), which may maintain ICL2 in a specific conformation and probably affect the ICL2-Gα<sub>s</sub> interaction pattern.

TM5 and TM6 with the outward movement of the cytoplasmic ends open a cytoplasmic cavity together with TM2, TM3, and helix 8 to accommodate the α5 helix of Gα<sub>s</sub>, constituting a major V2R-G<sub>s</sub> interface (Supplementary information, Fig. S7a). One additional interface relates to ICL2 that interacts with α5 helix, αN-β1 junction, and the top of the β3-strand of Gα<sub>s</sub>, presumably stabilized by hydrophobic contacts (Supplementary information, Fig. S7b). In contrast to the G<sub>s</sub>-coupled β<sub>2</sub>AR and A<sub>2A</sub>R structures, the cytoplasmic ends of TM5 and TM6 in V2R display a smaller amplitude of outward displacements (5.8 Å for TM5 and 8.7 Å for TM6 relative to β<sub>2</sub>AR,<sup>11</sup> 2.5 Å for TM5 and 7.2 Å for TM6 relative to A<sub>2A</sub>R,<sup>4</sup> measured at Ca carbon of residues 5.67 and 6.30,

respectively) (Fig. 1k, l). Also, a noticeable shift of G<sub>s</sub> protein in the AVP–V2R–G<sub>s</sub> complex may partly be caused by relatively inward positions of TM5 and TM6 that push the entire G<sub>s</sub> heterotrimer shifts in the same direction. Besides, the α5 helix of Gα<sub>s</sub> in the AVP–V2R–G<sub>s</sub> complex shifts half a helical turn away from the 7TM core (Fig. 1k). These structural differences altogether create a smaller cytoplasmic cavity to accommodate G<sub>s</sub> protein. Indeed, the solvent-accessible surface area (SASA) of the V2R–Gα<sub>s</sub> interface (943.32 Å<sup>2</sup>) is smaller than that of β<sub>2</sub>AR–Gα<sub>s</sub> (1,030 Å<sup>2</sup>) and A<sub>2A</sub>R–Gα<sub>s</sub> interfaces (1,276 Å<sup>2</sup>) (Supplementary information, Fig. S7c). Interestingly, compared to G<sub>s</sub>-coupled β<sub>2</sub>AR and A<sub>2A</sub>R, V2R exhibits a 1–2 helical turns shorter TM5 cytoplasmic end, which may be caused by a consecutive P–G–P sequence (P238, G239, and P240, residues known as α-helix breakers), resulting in fewer interactions between TM5 of V2R and Gα<sub>s</sub> subunit (Fig. 1; Supplementary information, Fig. S8).

In conclusion, we solved the cryo-EM structure of G<sub>s</sub>-coupled V2R bound to its endogenous ligand AVP. In this complex, AVP presents a unique cyclic conformation formed by an intramolecular disulfide bond and engages the orthosteric binding pocket of V2R in a ligand-specific mode. AVP-induced distortion of TM7 and a unique polar network formed by equivalent residues in the “P–I–F” motif may differentiate activation of V2R from other class A GPCRs. A smaller amplitude of the outward displacement of TM5 and TM6 and the concomitant shift of G<sub>s</sub> protein not only distinguish V2R from its counterparts but also represent a diversified G<sub>s</sub> coupling mechanism. Additionally, our structure is valuable to the mechanistic understanding of V2R mutation-associated diseases (Supplementary information, Fig. S9), while systematic investigations are required to enrich our knowledge in this regard. Together, our findings provide a framework for understanding AVP recognition and V2R activation, thereby offering a structural template for drug design targeting V2R.

#### ACCESSION CODES

The corresponding coordinates and cryo-EM density map have been deposited in the Protein Data Bank (<http://www.rcsb.org/pdb>) with code 7DW9, and in EMDB (<http://www.ebi.ac.uk/pdbe/emdb/>) with code EMD-30877.

#### ACKNOWLEDGEMENTS

We thank all staff members of the Cryo-EM Centre, Southern University of Science and Technology for their assistance in data collection. This work was partially supported by the Ministry of Science and Technology (China) grant (2018YFA0507002 to H.E.X.); National Natural Science Foundation of China (31770796 to Y.J., 81872915 to M.-W.W., 31600606 to X.Z., and 81773792 to D.Y.); National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program” (2018ZX09711002-002-002 to Y.J., 2018ZX09735-001 to M.-W.W., and 2018ZX09711002-002-005 to D.Y.); Shanghai Municipal Science and Technology Major Project (2019SHZDZX02 to H.E.X.); CAS Strategic Priority Research Program (XDB37030103 to H.E.X.); Start-up funding by Fudan University (Q.Z.); Wellcome Trust 209407/Z/17/Z; National Key R&D Program of China (2016YFA0501100 to X.Z.); Guangdong Provincial Key Laboratory of Brain Connectome and Behavior (2017B030301017 to X.Z.); CAS Key Laboratory of Brain Connectome and Manipulation (2019DP173024 to X.Z.).

#### AUTHOR CONTRIBUTIONS

F.Z. prepared samples for cryo-EM grid preparation; F.Z. and X.M. performed cryo-EM data collection and processing; F.Z., T.C., X.M., and X.Z. built and refined the structure

model; C.Y. and D.Y. conducted functional studies and data analysis; Q.Z. and X.H. carried out docking analysis; W.Y. engineered the mini-G<sub>s</sub> protein; F.Z. and Y.J. prepared the bulk of figures, performed the structural analysis, and drafted the manuscript; Y.J., H.E.X., and M.-W.W. supervised the studies, analyzed the data, and wrote the manuscript with inputs from all co-authors; P.W. supervised the EM studies.

#### ADDITIONAL INFORMATION

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41422-021-00480-2>.

**Competing interests:** The authors declare no competing interests.

Fulai Zhou<sup>1</sup>, Chenyu Ye<sup>2</sup>, Xiaomin Ma<sup>3</sup>, Wanchao Yin<sup>1</sup>,  
Tristan I. Croll<sup>4</sup>, Qingtong Zhou<sup>5</sup>, Xinheng He<sup>1,6</sup>,  
Xiaokang Zhang<sup>7,8</sup>, Dehua Yang<sup>1,6,9</sup>, Peiyi Wang<sup>3,10</sup>,  
H. Eric Xu<sup>1,6,11</sup>, Ming-Wei Wang<sup>1,2,5,6,9,11</sup> and Yi Jiang<sup>1,6</sup>  
<sup>1</sup>The CAS Key Laboratory of Receptor Research, Shanghai Institute of  
Materia Medica, Chinese Academy of Sciences, Shanghai 201203,  
China; <sup>2</sup>School of Pharmacy, Fudan University, Shanghai 201203,  
China; <sup>3</sup>Cryo-EM Centre, Southern University of Science and  
Technology, Shenzhen, Guangdong 515055, China; <sup>4</sup>Cambridge  
Institute for Medical Research, Department of Haematology,  
University of Cambridge, Cambridge CB2 0XY, UK; <sup>5</sup>School of Basic  
Medical Sciences, Fudan University, Shanghai 200032, China;  
<sup>6</sup>University of Chinese Academy of Sciences, Beijing 100049, China;  
<sup>7</sup>Interdisciplinary Center for Brain Information, The Brain Cognition  
and Brain Disease Institute, Shenzhen Institutes of Advanced  
Technology, Chinese Academy of Sciences, Shenzhen, Guangdong  
518055, China; <sup>8</sup>Shenzhen-Hong Kong Institute of Brain Science-  
Shenzhen Fundamental Research Institutions, Shenzhen, Guangdong  
518055, China; <sup>9</sup>The National Center for Drug Screening, Shanghai  
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai  
201203, China; <sup>10</sup>Department of Biology, Southern University of  
Science and Technology, Shenzhen, Guangdong 515055, China and  
<sup>11</sup>School of Life Science and Technology, ShanghaiTech University,  
Shanghai 201210, China  
These authors contributed equally: Fulai Zhou, Chenyu Ye, and  
Xiaomin Ma  
Correspondence: Peiyi Wang ([wangpy@sustech.edu.cn](mailto:wangpy@sustech.edu.cn)) or H Eric Xu  
([eric.xu@simmm.ac.cn](mailto:eric.xu@simmm.ac.cn)) or Ming-Wei Wang ([mwwang@simmm.ac.cn](mailto:mwwang@simmm.ac.cn)) or  
Yi Jiang ([yijiang@simmm.ac.cn](mailto:yijiang@simmm.ac.cn))

#### REFERENCES

- Barberis, C., Mouillac, B. & Durroux, T. *J. Endocrinol.* **156**, 223–229 (1998).
- Donaldson, Z. R. & Young, L. J. *Science* **322**, 900–904 (2008).
- Makita, N., Manaka, K., Sato, J. & Iiri, T. *Vitam. Horm.* **113**, 79–99 (2020).
- Carpenter, B., Nehme, R., Warne, T., Leslie, A. G. & Tate, C. G. *Nature* **538**, 104–107 (2016).
- Ballesteros, J. A. & Weinstein, H. *Methods Neurosci.* **25**, 366–428 (1995).
- Tahara, A. et al. *Br. J. Pharmacol.* **125**, 1463–1470 (1998).
- Conner, M. et al. *J. Biol. Chem.* **282**, 17405–17412 (2007).
- Waltenspuhl, Y., Schoppe, J., Ehrenmann, J., Kummer, L. & Pluckthun, A. *Sci. Adv.* **6**, eabb5419 (2020).
- Zhou, Q. et al. *Elife* **8**, e50279 (2019).
- Wisniewski, K. et al. *J. Med. Chem.* **54**, 4388–4398 (2011).
- Rasmussen, S. G. et al. *Nature* **477**, 549–555 (2011).
- Erdélyi, L. et al. *Endocrine Abstracts* **49**, <https://doi.org/10.1530/endoabs.49.EP804> (2017).
- Wenkert, D. et al. *Mol. Cell Endocrinol.* **124**, 43–50 (1996).
- Chini, B. et al. *FEBS Lett.* **397**, 201–206 (1996).